Trust Point Inc. Invests $556,000 in Balchem Co. (NASDAQ:BCPC)

Trust Point Inc. acquired a new stake in Balchem Co. (NASDAQ:BCPC) during the 4th quarter, HoldingsChannel reports. The firm acquired 3,736 shares of the basic materials company’s stock, valued at approximately $556,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BCPC. Operose Advisors LLC bought a new position in shares of Balchem in the third quarter worth $31,000. Quantbot Technologies LP bought a new position in shares of Balchem in the first quarter worth $34,000. Gyon Technologies Capital Management LP bought a new position in shares of Balchem in the fourth quarter worth $56,000. Point72 Hong Kong Ltd bought a new position in Balchem in the first quarter valued at $67,000. Finally, Point72 Middle East FZE bought a new position in Balchem in the fourth quarter valued at $84,000. Institutional investors own 87.91% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a research note on Wednesday, February 21st.

Insider Transactions at Balchem

In other news, CAO William A. Backus sold 7,000 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $155.19, for a total transaction of $1,086,330.00. Following the completion of the sale, the chief accounting officer now directly owns 5,914 shares in the company, valued at $917,793.66. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Theodore L. Harris sold 34,350 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $154.29, for a total transaction of $5,299,861.50. Following the completion of the sale, the chief executive officer now owns 66,412 shares of the company’s stock, valued at $10,246,707.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William A. Backus sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $155.19, for a total transaction of $1,086,330.00. Following the sale, the chief accounting officer now directly owns 5,914 shares of the company’s stock, valued at approximately $917,793.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,630 shares of company stock worth $11,843,249. Company insiders own 1.77% of the company’s stock.

Balchem Stock Performance

NASDAQ BCPC opened at $150.87 on Friday. The company has a 50-day simple moving average of $151.13 and a two-hundred day simple moving average of $137.76. The company has a quick ratio of 1.38, a current ratio of 2.12 and a debt-to-equity ratio of 0.31. Balchem Co. has a 12-month low of $110.74 and a 12-month high of $159.52. The firm has a market cap of $4.87 billion, a price-to-earnings ratio of 45.04, a PEG ratio of 4.55 and a beta of 0.71.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.02. Balchem had a net margin of 11.77% and a return on equity of 10.69%. The business had revenue of $228.70 million during the quarter, compared to analyst estimates of $234.66 million. During the same period in the prior year, the business posted $0.66 earnings per share. The company’s revenue was down 1.6% on a year-over-year basis. On average, equities analysts forecast that Balchem Co. will post 4.14 EPS for the current year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.